Novartis' heart failure drug faces hurdles despite upbeat PhIII results – FierceBiotech
TopNews United StatesNovartis' heart failure drug faces hurdles despite upbeat PhIII resultsFierceBiotechNovartis has detailed the hits and misses from a late-stage trial of its potential blockbuster therapy for acute heart failure, serelaxin, call…